TY - JOUR
T1 - An international pragmatic randomized controlled trial to compare a single-use negative-pressure dressing versus the surgeon's preference of dressing to reduce the incidence of surgical site infection following emergency laparotomy: the SUNRRISE trial protocol
AU - Wilkin, Richard
AU - Coe, Peter
AU - Duarte, Rui
AU - Stott, Martyn
AU - Pockney, Peter
AU - Egoroff, Natasha
AU - Mehta, Samir
AU - Brown, James
AU - Magill, Laura
AU - Ives, Natalie
AU - Fish, Rebecca
AU - Glasbey, James
AU - Duff, Sarah
AU - Pinkney, Thomas D.
AU - Clouston, Hamish
N1 - Funding Information:
We would like to acknowledge the input from Professor Jon Gani (University of Newcastle, Australia), Professor Michael Solomon (University of Sydney), Professor Sandy Heriott (University of Melbourne), Professor John Attia (University of Newcastle, Australia), Dr Alison Blatt (John Hunter Hospital) and Dr Ani Deshpande (Westmead Childrens? Hospital) who have provided local trial oversight in Australia. Organizational structure and responsibilities are as follows. Trial management group (UK): James Brown, Hamish Clouston, Peter Coe, Rui Duarte, Sarah Duff, Rebecca Fish, Paula Ghaneh, James Glasbey, Natalie Ives, Elisabeth Johnstone, Manjinder Kaur, Laura Magill, Samir Mehta, Thomas Pinkney, Kellie Platt, Peter Pockney, Hema Sekhar, Yash Sinha, Martyn Stott, Richard Wilkin. Trial management group (Australia): Hossein Afzali, Thomas Arthur, Amanda Dawson, Nagendra N. Dudi-Venkata, Natasha Egoroff, Madelyn Gramlick, Yick Ho Lam, Vijayaragavan Muralidharan, Sean S. W. Park, Peter Pockney, Toby Richards, Tarik Sammour, Bree Stephensen, Sean Stevens, Uyen Giao Vo, David Watson, Richard Wilkin. Data Monitoring Committee: Nigel Hall (chair), Joanne Dumville, Ly-Mee Yu. Trial Steering Committee: Matt Costa (chair), Neil Corrigan, Marcos Gomez Ruiz, Lesley Osborn (patient representative).
Funding Information:
SUNRRISE is funded by the Research for Patient Benefit programme from the National Institute for Health Research (NIHR) in the UK and the Medical Research Future Fund (MRFF) International Clinical Trials Collaboration Program in Australia. The interventional arm dressings are supplied for the trial by Smith & Nephew who also distribute the dressings to the sites involved. At each site the company is providing dressing application and management training to local teams in line with their usual training support for sites using their dressings. This training is for general use of their PICO dressings and not specific to the trial and does not cover any part of the trial protocol or participant management. SUNRRISE is an investigator‐initiated study, and the design, management, analysis and reporting are entirely independent from the funders, including Smith & Nephew. The academic investigators retain full independence and autonomy for study conduct and reporting. This paper presents independent research funded by the NIHR under its Research for Patient Benefit (RfPB) Programme (PB‐PG‐0416‐20045) and the MRFF International Clinical Trials Collaboration (ICTC) Program (MRFF1179938). The views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care or the Commonwealth of Australia. Primary trial sponsor: University of Birmingham (UK). Sponsor's reference: RG_17‐239, Research Governance Team, University of Birmingham, Birmingham B15 2 TT ( [email protected] ). Secondary trial sponsor: University of Newcastle (Australia), Research and Innovation Services, University of Newcastle, Callaghan 2308 ( [email protected] ).
Publisher Copyright:
© 2020 Association of Coloproctology of Great Britain and Ireland.
PY - 2021/4/19
Y1 - 2021/4/19
N2 - Aim: Surgical site infection (SSI) is a common complication following emergency laparotomy, occurring in around 25% of patients in UK practice. The adoption of single-use negative-pressure dressings (SUNPDs) has been proposed as a prophylactic method of reducing the rate of SSI. The primary aim of the randomized controlled trial (RCT) described herein is to determine if a SUNPD reduces SSI at 30 days after an emergency laparotomy. Method: The Single Use Negative pRessure dressing for Reduction In Surgical site infection following Emergency laparotomy (SUNRRISE) study is an international, multicentre, pragmatic, phase III RCT with internal feasibility phase. As stated, the primary aim is to determine if a SUNPD reduces SSI at 30 days postoperatively. Patients will be randomized in a 1:1 ratio to receive either a SUNPD or a dressing of the surgeon's preference. Outcome assessors will be blinded to treatment allocation. The primary outcome measure is SSI within 30 days of surgery as defined by the US Centers for Disease Control criteria. A total of 840 patients will be required to detect a relative reduction of 40% in SSI rates (from 25% to 15%) with 90% power accounting for a 20% attrition rate. Discussion: SUNRRISE is an international, multicentre RCT evaluating the prophylactic use of SUNPD in primary closed emergency laparotomy wounds for the reduction of SSI. Our hypothesis is that a SUNPD is superior to the surgeon's preference of dressing in reducing SSIs at 30 days. The findings may influence dressing choice following emergency abdominal surgery in the future.
AB - Aim: Surgical site infection (SSI) is a common complication following emergency laparotomy, occurring in around 25% of patients in UK practice. The adoption of single-use negative-pressure dressings (SUNPDs) has been proposed as a prophylactic method of reducing the rate of SSI. The primary aim of the randomized controlled trial (RCT) described herein is to determine if a SUNPD reduces SSI at 30 days after an emergency laparotomy. Method: The Single Use Negative pRessure dressing for Reduction In Surgical site infection following Emergency laparotomy (SUNRRISE) study is an international, multicentre, pragmatic, phase III RCT with internal feasibility phase. As stated, the primary aim is to determine if a SUNPD reduces SSI at 30 days postoperatively. Patients will be randomized in a 1:1 ratio to receive either a SUNPD or a dressing of the surgeon's preference. Outcome assessors will be blinded to treatment allocation. The primary outcome measure is SSI within 30 days of surgery as defined by the US Centers for Disease Control criteria. A total of 840 patients will be required to detect a relative reduction of 40% in SSI rates (from 25% to 15%) with 90% power accounting for a 20% attrition rate. Discussion: SUNRRISE is an international, multicentre RCT evaluating the prophylactic use of SUNPD in primary closed emergency laparotomy wounds for the reduction of SSI. Our hypothesis is that a SUNPD is superior to the surgeon's preference of dressing in reducing SSIs at 30 days. The findings may influence dressing choice following emergency abdominal surgery in the future.
KW - PICO dressing
KW - randomized controlled trial
KW - surgical site infection
KW - topical negative pressure dressing
KW - wound infection
U2 - 10.1111/codi.15474
DO - 10.1111/codi.15474
M3 - Article
SN - 1462-8910
VL - 23
SP - 989
EP - 1000
JO - Colorectal Disease
JF - Colorectal Disease
IS - 4
ER -